News

Orca-T Cell Therapy Shows Superior Survival Over Standard Transplant Approach in AML and MDS

Treatment /

A new study suggests that the precision cell therapy Orca-T may outperform the current standard treatment, post-transplant cyclophosphamide (PTCy), for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing stem cell transplants. In this retrospective analysis, patients treated with Orca-T showed notably better outcomes than those who received PTCy. Two-year overall survival reached […]

Orca-T Cell Therapy Shows Superior Survival Over Standard Transplant Approach in AML and MDS Read More »

New Computational Tool Reveals Why Pancreatic Cancer Spreads and Evades Treatment

Research Advances /

and Evades Treatment Researchers have developed a new computational tool, FunCN (Functional Cellular Neighborhoods), to better understand how pancreatic cancer spreads and resists treatment. Unlike older methods that look at only nearby cells, FunCN measures how all surrounding cells influence each other, giving a more detailed map of the tumor microenvironment. Using FunCN, the team

New Computational Tool Reveals Why Pancreatic Cancer Spreads and Evades Treatment Read More »

FDA Grants Breakthrough Therapy Designation to Plixorafenib for Aggressive BRAF-Mutated Brain Tumors

Drug Approvals /

The FDA has granted Breakthrough Therapy Designation to plixorafenib (FORE8394) for adults with BRAF V600E–mutated high-grade glioma, aiming to speed up its development and review. Plixorafenib is an oral, next-generation BRAF inhibitor designed to work on multiple BRAF mutations while reducing side effects compared with earlier drugs. Early trials show a 67% overall response rate

FDA Grants Breakthrough Therapy Designation to Plixorafenib for Aggressive BRAF-Mutated Brain Tumors Read More »

CMS Issues Permanent Billing Code for Inlexzo, Improving Access for Bladder Cancer Patients

Treatment /

The Centers for Medicare & Medicaid Services (CMS) has issued a permanent billing code (J9183) for Inlexzo, the first FDA-approved intravesical system delivering gemcitabine directly to the bladder. This change makes billing easier for healthcare providers and helps patients access the therapy more quickly. Inlexzo, approved in September 2025, treats patients with BCG-unresponsive non-muscle invasive

CMS Issues Permanent Billing Code for Inlexzo, Improving Access for Bladder Cancer Patients Read More »

Proton and Standard Radiation Show Similar Long-Term Outcomes in Oropharyngeal Cancer Trial

Treatment /

The Phase 3 TORPEdO trial compared intensity-modulated proton therapy (IMPT) with standard intensity-modulated radiation therapy (IMRT) in 205 patients with locally advanced oropharyngeal cancer. Both groups received the same radiation dose and chemotherapy. The study aimed to see if proton therapy could reduce side effects by sparing healthy tissues. IMPT showed a slight functional advantage

Proton and Standard Radiation Show Similar Long-Term Outcomes in Oropharyngeal Cancer Trial Read More »

FDA Grants Full Approval to Tecartus for Mantle Cell Lymphoma, Expanding Early Treatment Options

Drug Approvals /

The FDA has given full approval to brexucabtagene autoleucel (Tecartus) for adults with relapsed or refractory mantle cell lymphoma (MCL), upgrading its previous accelerated approval. This decision is based on data from the ZUMA-2 trial, including patients who had not yet received BTK inhibitors. In this group, Tecartus showed a 91% overall response rate and

FDA Grants Full Approval to Tecartus for Mantle Cell Lymphoma, Expanding Early Treatment Options Read More »

Four-Drug Combination Therapy Shows Promise in Improving Outcomes for Liver Cancer Patients

Treatment /

The Phase 3 EMERALD-3 trial has shown that a four-drug combination treatment can significantly delay disease progression in patients with unresectable hepatocellular carcinoma (HCC) who are eligible for embolization. The study tested a combination of STRIDE therapy (tremelimumab and durvalumab), lenvatinib, and TACE, compared with TACE alone. Results showed that adding these therapies led to

Four-Drug Combination Therapy Shows Promise in Improving Outcomes for Liver Cancer Patients Read More »

Microbial “Fingerprint” Discovery Could Transform Colorectal Cancer Diagnosis and Treatment

Research Advances /

A new study shows that colorectal cancer has a unique microbial “fingerprint” that sets it apart from other cancers. Researchers analyzed genetic data from more than 9,000 patients and found that, unlike most cancers, colorectal tumors consistently carry distinct patterns of microbes. This means studying the microbes inside tumors could become a simple and cost-effective

Microbial “Fingerprint” Discovery Could Transform Colorectal Cancer Diagnosis and Treatment Read More »

Pancreatic Cancer Treatment Moves Toward Personalized Medicine with New Targeted Therapies

Targeted Therapy /

Pancreatic cancer treatment is beginning to shift from traditional chemotherapy to a more personalized approach, according to a new review. Although survival rates remain low, recent advances targeting genetic mutations and the tumor environment are starting to improve outcomes. For most patients, combination chemotherapy is still the standard treatment. Regimens like FOLFIRINOX or NALIRIFOX are

Pancreatic Cancer Treatment Moves Toward Personalized Medicine with New Targeted Therapies Read More »

CD276 Identified as Key Driver of Chemotherapy Resistance in Pancreatic Cancer Study

Research Advances /

A major study reveals how chemotherapy reshapes the environment around pancreatic tumors, helping explain why some patients do not respond to treatment. Using advanced single-cell and spatial analysis, researchers identified a “chemoresistant niche” where aggressive tumor cells, immune-suppressing macrophages, and exhausted T cells work together to protect the cancer. The study highlights CD276 (also known

CD276 Identified as Key Driver of Chemotherapy Resistance in Pancreatic Cancer Study Read More »